{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:41Z","timestamp":1787019641148,"version":"build-2736575974"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Systemic light chain (AL) amyloidosis is a protein misfolding disorder characterized by the deposition of abnormal immunoglobulin light chains in fibrillary aggregates, resulting in end-organ damage. Several unique challenges face treating physicians, including delayed diagnosis, advanced vital organ involvement, and morbidity with treatment. Aggressive supportive care and risk-adapted application of plasma cell\u2013directed therapies are the cornerstones of management. The therapeutic revolution in multiple myeloma will likely further expand the arsenal against plasma cells. Careful investigation of these agents will be critical to establish their role in this fragile population. The promise of fibril-directed therapies to restore organ function remains despite early disappointments. In this review, we discuss new therapies to tackle AL amyloidosis using a case-based approach.<\/jats:p>","DOI":"10.1182\/hematology.2021000305","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T07:21:36Z","timestamp":1639120896000},"page":"682-688","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["AL amyloidosis: untangling new therapies"],"prefix":"10.1182","volume":"2021","author":[{"given":"Susan","family":"Bal","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Landau","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"10","key":"2021121012092139200_hem2021000305C1","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the amyloidosis research consortium","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv Ther"},{"issue":"6","key":"2021121012092139200_hem2021000305C2","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"issue":"19","key":"2021121012092139200_hem2021000305C3","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro\u2013brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"issue":"8","key":"2021121012092139200_hem2021000305C4","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"issue":"19","key":"2021121012092139200_hem2021000305C5","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2021121012092139200_hem2021000305C6","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2021121012092139200_hem2021000305C7","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2021121012092139200_hem2021000305C8","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"issue":"18","key":"2021121012092139200_hem2021000305C9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2021121012092139200_hem2021000305C10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"36","key":"2021121012092139200_hem2021000305C11","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021121012092139200_hem2021000305C12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"4","key":"2021121012092139200_hem2021000305C13","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.3324\/haematol.2017.178095","article-title":"Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis","volume":"103","author":"Manwani","year":"2018","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2021121012092139200_hem2021000305C14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2020-137582","article-title":"Reduction in absolute involved free light chain and difference between involved and uninvolved free light chain is associated with prolonged major organ deterioration progression-free survival in patients with newly diagnosed AL amyloidosis receiving bortezomib, cyclophosphamide, and dexamethasone with or without daratumumab: results from andromeda","volume":"136","author":"Comenzo","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2021121012092139200_hem2021000305C15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-021-00428-0","article-title":"Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis","volume":"11","author":"Palladini","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"2021121012092139200_hem2021000305C16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-020-0291-8","article-title":"Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis","volume":"10","author":"Dispenzieri","year":"2020","journal-title":"Blood Cancer J"},{"issue":"20","key":"2021121012092139200_hem2021000305C17","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2021121012092139200_hem2021000305C18","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","article-title":"Stem cell transplantation for light chain amyloidosis: decreased early mortality over time","volume":"36","author":"Sidiqi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021121012092139200_hem2021000305C19","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.3324\/haematol.2014.108191","article-title":"Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting","volume":"99","author":"Venner","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"2021121012092139200_hem2021000305C20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.echo.2017.08.017","article-title":"Prognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantation","volume":"31","author":"Pun","year":"2018","journal-title":"J Am Soc Echocardiogr"},{"issue":"2","key":"2021121012092139200_hem2021000305C21","article-title":"Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial","volume":"12","author":"Huang","year":"2014","journal-title":"BMC Med"},{"issue":"4","key":"2021121012092139200_hem2021000305C22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1080\/13506129.2016.1258356","article-title":"Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation","volume":"23","author":"Cowan","year":"2016","journal-title":"Amyloid"},{"issue":"22","key":"2021121012092139200_hem2021000305C23","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V128.22.645.645","article-title":"Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012092139200_hem2021000305C24","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1182\/blood-2019-126567","article-title":"A phase 1 study of carfilzomib-thalidomide-dexamethasone in patients with relapsed\/refractory AL amyloidosis\u2014 catalyst trial results","volume":"134","author":"Garg","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2021121012092139200_hem2021000305C25","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A phase \u00bd study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2021121012092139200_hem2021000305C26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2019-124409","article-title":"Primary results from the phase 3 tourmaline-AL1 trial of ixazomib-dexamethasone versus physician's choice of therapy in patients (Pts) with relapsed\/refractory primary systemic AL amyloidosis (RRAL)","volume":"134","author":"Dispenzieri","year":"2019","journal-title":"Blood"},{"issue":"23","key":"2021121012092139200_hem2021000305C27","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1182\/blood-2011-12-396903","article-title":"A phase \u00bd study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis","volume":"119","author":"Kastritis","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2021121012092139200_hem2021000305C28","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood"},{"issue":"15","key":"2021121012092139200_hem2021000305C29","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2021121012092139200_hem2021000305C30","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2007-11-122101","article-title":"Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability","volume":"111","author":"Bochtler","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2021121012092139200_hem2021000305C31","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021121012092139200_hem2021000305C32","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"2021121012092139200_hem2021000305C33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41408-020-0321-6","article-title":"Venetoclax for the treatment of translocation (11;14) AL amyloidosis","volume":"10","author":"Sidiqi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"2021121012092139200_hem2021000305C34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2021121012092139200_hem2021000305C35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-143180","article-title":"A phase II study of isatuximab (SAR650984) (NSC-795145) for patients with previously treated AL Amyloidosis (SWOG S1702; NCT#03499808)","volume":"136","author":"Parker","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2021121012092139200_hem2021000305C36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.23898","article-title":"Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis","volume":"90","author":"Kaufman","year":"2015","journal-title":"Am J Hematol"},{"issue":"5","key":"2021121012092139200_hem2021000305C37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4155\/ppa-2017-0022","article-title":"Pretargeting immunotherapy: a novel treatment approach for systemic amyloidosis","volume":"6","author":"Wall","year":"2017","journal-title":"Pharm Pat Anal"},{"issue":"422","key":"2021121012092139200_hem2021000305C38","doi-asserted-by":"crossref","first-page":"eaan3128","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis","volume":"10","author":"Richards","year":"2018","journal-title":"Sci Transl Med"},{"issue":"suppl 1","key":"2021121012092139200_hem2021000305C39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/13506129.2017.1292900","article-title":"Interim analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis","volume":"24","author":"Edwards","year":"2017","journal-title":"Amyloid"},{"key":"2021121012092139200_hem2021000305C40","doi-asserted-by":"crossref","first-page":"100361","DOI":"10.1016\/j.eclinm.2020.100361","article-title":"Adjuvant doxycycline to enhance anti-amyloid effects: results from the dual phase 2 trial","volume":"23","author":"D'Souza","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"1","key":"2021121012092139200_hem2021000305C41","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/s41467-020-17459-z","article-title":"Accelerated single cell seeding in relapsed multiple myeloma","volume":"11","author":"Landau","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"2021121012092139200_hem2021000305C42","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.hoc.2020.08.006","article-title":"Solid organ transplantation","volume":"34","author":"Bal","year":"2020","journal-title":"Hematol Oncol Clin North Am"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/682\/1851838\/682bal.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/682\/1851838\/682bal.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T07:22:01Z","timestamp":1639120921000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/682\/482948\/AL-amyloidosis-untangling-new-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000305","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}